Cybin is trading at $7.72 (+8.58%) following fresh momentum around its late-stage depression program and a successful capital raise.
- The APPROACH Phase 3 trial has surpassed 86% enrollment and remains on track for a topline readout in Q4 2026.
- The move is supported by a $50 million equity raise, allowing the stock to outperform a broader biotech sector that is currently trading lower.